AstraZeneca Inks $555M AI-CRISPR Deal with Algen to Target Immunology
AstraZeneca has signed a $555 million milestone-based partnership with Algen Biotechnologies to deploy AI and CRISPR gene-editing together for immunology drug discovery.
AstraZeneca has signed a $555 million milestone-based partnership with Algen Biotechnologies to deploy AI and CRISPR gene-editing together for immunology drug discovery.
April 8th, 2026
April 8th, 2026
April 8th, 2026
April 7th, 2026
April 7th, 2026